| Cash Flow | 2026-06-30 |
|---|---|
| Net loss | -97,779 |
| Depreciation and amortization | 1,199 |
| Accretion of discounts on marketable securities | 208 |
| Stock-based compensation expense | 4,938 |
| Non-cash interest expense | 133 |
| Non-cash lease expense | 3,353 |
| Change in fair value of simple agreement for future equity | 5,556 |
| Rent receivable - related party | 0 |
| Due from related party | 0 |
| Prepaid expenses and other assets | 5,364 |
| Operating lease liabilities | -3,510 |
| Deferred revenue | 41,519 |
| Accounts payable, accrued expenses and other liabilities | -2,659 |
| Net cash used in operating activities | -52,822 |
| Purchases of marketable securities | 33,447 |
| Proceeds from maturities of marketable securities | 0 |
| Purchases of property and equipment | 985 |
| Net cash (used in) provided by investing activities | -34,432 |
| Proceeds from issuance of convertible preferred stock-Series EConvertible Preferred Stock | 0 |
| Proceeds from issuance of convertible preferred stock-Series FConvertible Preferred Stock | 305,249 |
| Payments of convertible preferred stock issuance costs | 680 |
| Proceeds from issuance of simple agreement for future equity | 50,000 |
| Proceeds from initial public offering, net of underwriting discounts and commissions | 718,240 |
| Payments of initial public offering costs | 2,499 |
| Proceeds from concurrent private placement of common stock | 83,333 |
| Principal payments on finance leases | 311 |
| Principal payments on debt | 7,500 |
| Proceeds from exercise of stock options | 771 |
| Net cash provided by financing activities | 1,146,603 |
| Increase in cash, cash equivalents and restricted cash | 1,059,349 |
| Cash, cash equivalents and restricted cash at beginning of period | 30,566 |
| Cash, cash equivalents and restricted cash at end of period | 1,089,915 |
Parabilis Medicines, Inc. (PBLS)
Parabilis Medicines, Inc. (PBLS)